Monoclonal Antibodies that React with Cell Surface Molecules on Human Pancreatic Duct Cells, Endocrine (Islet) Cells, Exocrine Cells and Alpha Cells
OHSU # 1038
Diabetes is a common disease affecting millions of individuals in the United States. Type 1 diabetes occurs when pancreatic islet beta-cells are destroyed as a consequence of an autoimmune disorder. Despite improvements in the medical management of diabetes, severe complications and shortened life-span are still common in individuals with this disease. Cell replacement therapy can work in type 1 diabetes as shown by the success of islet transplantation from cadaveric donors in the Edmonton protocol. Unfortunately, the supply of transplantable islets is completely inadequate and thus cell therapy remains a promissory note in the therapeutic arsenal at this time.
Novel technology will be required to enable the broad application of cell therapy in patients with diabetes. Technologies that may positively and rapidly impact islet or beta-cell availability for transplant include those that: 1) increase the yield of islets and/or islet beta-cells from deceased donors, 2) facilitate generation of islets and/or islet beta-cells in ex vivo cell/organ culture systems, and 3) allow purification of islets and/or islet beta-cells following ex vivo culture.
The available antibodies include the following:
· HPi1 from hybridoma HIC0-4F9 (endocrine cell marker)
· HPi2 from hybridoma HIC1-2B4 (endocrine cell marker)
· HPi4 from hybridoma HIC1-5F10 (endocrine cell marker)
· HPi3 from hybridoma HIC1-7H10 (endocrine cell marker)
· HPa1 from hybridoma DHIC2 2-C12 (alpha cell marker)
· HPa2 from hybridoma DHIC2 2-B4 (alpha cell marker)
· HPx2 from hybridoma HIC1 1-C10 (exocrine cell marker)
· HPd1 from hybridoma DHIC2 4-A10 (duct cell marker)
· HPd2 from hybridoma DHIC3 5-H10 (duct cell marker)
· Antibody from hybridoma HIC1 4-G6 (endocrine cell marker)
· Antibody from hybridoma HIC0 3-C5 (endocrine cell marker)
These novel anti-human pancreatic monoclonal antibodies are specific for either pancreatic endocrine cells, alpha cells, exocrine cells or duct cells. These antibodies may be used for cell isolation based upon their cell surface marker specificity. These antibodies may also have a significant impact on the development of additional technology for therapy of diabetes mellitus. For example, they may provide a rapid screening tool to assess expansion and/or differentiation of functional pancreatic cell types. Furthermore, these antibodies may also impact clinical application of cell products intended for treatment of Type I Diabetes, as reagents that could be used to assess cell subset purity and/or potency. Finally, these antibodies may have applications as immunohistochemical reagents to assess pancreatic cell function in vivo or in vitro. Overall, there are many potential uses for these antibodies.
No other antibodies with such specificity are known to exist.
Dr. Grompe received his medical degree in 1982 at the University of Ulm Medical School in Germany. From 1984-1987 Dr. Grompe was trained in Pediatrics at Oregon Health Sciences University in Portland, Oregon, USA and then moved to Baylor College of Medicine in Houston, Texas. There he was a fellow sponsored by the Pediatric Scientist Training Program in the Institute for Molecular Genetics from 1987-1991 and worked on gene therapy for inherited diseases, particularly metabolic liver disorders. In 1991, Dr. Grompe joined the faculty at Oregon Health & Science University and he is currently Professor in the Departments of Molecular and Medical Genetics and Pediatrics. He is a recipient of the E. Mead Johnson award for pediatric research (2002) and the Merit Award of the Fanconi Anemia Research Foundation (2002). He is involved in the clinical care of patients with genetic diseases as well as scientific investigation. In 2004 he became the first director of the newly founded Oregon Stem Cell Center.
Dr. Streeter received his B.S. from the University of California-Davis in 1977. He attended graduate school at Kansas State University, receiving an M.S. in Laboratory Medicine in 1980 and a Ph.D. in Microbiology, with a focus on tumor immunobiology in 1985. After completing his Ph.D., Dr. Streeter studies as a Postdoctoral Fellow in the Department of Pathology at Stanford University. In 1989 Dr. Streeter joined the biotechnology company SyStemix Inc., Palo Alto, CA, as a scientist. He moved to St. Louis, MO. in 1992 to work at Searle/Monsanto, now Pfizer, where he led research efforts in the engineering of hematopoietic cytokines, the development of tumor vaccines, and development of selective inhibitors of autoimmune disease. Dr. Streeter joined Oregon Health & Science University as an Assistant Professor in the Department of Medicine in 2000. He is a member of the OHSU Center for Hematologic Malignancies and the Oregon Stem Cell Center. In 2003 he became Laboratory Director of the OHSU Hematopoietic Cell Processing Laboratory, and he is currently Director of the Flow Cytometry and Monoclonal Antibody Core Laboratories in the Oregon Stem Cell Center.
The extent of potential applications for use of these antibodies is continuing to be explored.
The antibodies and patent rights are available for non-exclusive licensing for specific fields of use.
- Markus Grompe, SM.Molecular & Medical Genetics
- Philip Streeter, SM.Medicine
- Craig Dorrell, SM.Molecular & Medical Genetics
- Stephanie Abraham, SM.Molecular & Medical Genetics
- Kelsea Shoop, SM.Molecular & Medical Genetics
|Published||Patent Cooperation Treaty||WO/2007/127476|
Other Patents Filed
- OHSU # 1038A — HPi1 Monoclonal Antibody Supernatant from Hybridoma HIC0 4-F9 (endocrine cell marker)
- OHSU # 1038B — HPi2 Monoclonal Antibody Supernatant from Hybridoma HIC1 2-B4 (endocrine cell marker)
- OHSU # 1038D — HPi4 Monoclonal Antibody Supernatant from Hybridoma HIC1 5-F10 (endocrine cell marker)
- OHSU # 1038E — HPi3 Monoclonal Antibody Supernatant from Hybridoma HIC1 7-H10 (endocrine cell marker)
- OHSU # 1038G — HPa1 Monoclonal Antibody Supernatant from Hybridoma DHIC2 2-C12 (alpha cell marker)
- OHSU # 1038H — HPa2 Monoclonal Antibody Supernatant from Hybridoma DHIC2-2B4 (alpha cell marker)
- OHSU # 1038I — HPx2 Monoclonal Antibody Supernatant from Hybridoma HIC1 1-C10 (exocrine cell marker)
- OHSU # 1038J — HPd1 Monoclonal Antibody Supernatant from Hybridoma DHIC2 4-A10 (duct cell marker)
- OHSU # 1038K — HPd2 Monoclonal Antibody Supernatant from Hybridoma DHIC3 5-H10 (duct cell marker)
- OHSU # 1298 — HPx1 Monoclonal Antibody Supernatant from Hybridoma HIC0-3B3 (exocrine cell marker)
For more information, contact:
Technology Development Manager